Tumorigenesis and immune function in a transgenic mouse model of the endocrine changes seen in depression characterized by defective glucocorticoid feedback inhibition and HPA axis hyperactivity (Unbekannt)
- Neue Suche nach: Blom, J. M. C.
- Neue Suche nach: Barden, N.
- Neue Suche nach: Racagni, G.
- Neue Suche nach: Blom, J. M. C.
- Neue Suche nach: Barden, N.
- Neue Suche nach: Racagni, G.
In:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
;
5
, 3
;
244
;
1995
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Tumorigenesis and immune function in a transgenic mouse model of the endocrine changes seen in depression characterized by defective glucocorticoid feedback inhibition and HPA axis hyperactivity
-
Beteiligte:
-
Erschienen in:EUROPEAN NEUROPSYCHOPHARMACOLOGY ; 5, 3 ; 244
-
Verlag:
- Neue Suche nach: ELSEVIER SCIENCE BV
-
Erscheinungsdatum:01.01.1995
-
Format / Umfang:244 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Unbekannt
- Neue Suche nach: 616.8 / 615.1
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
-
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 5, Ausgabe 3
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 159
-
Personality disorders are disorders of the personality?Lopez-Ibor, J. J. et al. | 1995
- 159
-
Metabotropic receptors: ten years of researchBockaert, J. et al. | 1995
- 160
-
The dopamine and glutamate hypotheses of schizophrenia - therapeutic implications of an integrated viewCarlsson, A. et al. | 1995
- 161
-
Peripheral markers in obsessive-compulsive disorder: effect of treatmentsMarazziti, D. / Pfanner, C. / Rossi, A. / Gemignani, A. et al. | 1995
- 161
-
The relevance of behavioral probes in obsessive-compulsive disorderDolberg, O. T. / Sasson, Y. / Cohen, R. / Zohar, J. et al. | 1995
- 162
-
Treating obsessive-compulsive disorder with serotonin reuptake inhibitorsKoran, L. M. et al. | 1995
- 163
-
Treatment of severe OCDGoodman, W. K. / Byerly, M. / Murphy, T. et al. | 1995
- 163
-
The use of antiandrogen therapy in refractory obsessive-compulsive male patientsCasas, M. / Barcia, D. / Vallejo, J. / Turon, V. et al. | 1995
- 164
-
Movement disorders in schizophrenia: current considerationsCasey, D. E. et al. | 1995
- 164
-
Imaging of neuroleptic occupancy in schizophreniaKerwin, R. / Pilowsky, L. / Busatto, G. / Costa, D. et al. | 1995
- 165
-
Update on new atypical antipsychoticsTollefson, G. D. et al. | 1995
- 165
-
Reintegration strategies in schizophrenia: maximizing outcomesLittrell, K. H. et al. | 1995
- 165
-
Health economic considerations in the treatment of schizophreniaSouetre, E. et al. | 1995
- 166
-
Alpha-2 adrenergic dysfunction in depression: standardization and validation of the clonidine REM suppression test (CREST)Schittecatte, M. et al. | 1995
- 167
-
Affective disorder treatments and second messengers in the brainMoerk, A. / Jensen, J. B. / Petersen, B. / Thrane, J. et al. | 1995
- 167
-
The comparative effects of SSRIs and TCAs on sleep architectureNutt, D. J. et al. | 1995
- 168
-
Long-term SSRI treatment increases Ca^2^+/calmodulin phosphorylation of presynaptic proteins: a new site in the mechanism of action of antidepressantsPopoli, M. / Vocaturo, C. / Buffa, L. / Pereza, J. et al. | 1995
- 168
-
The stress-induced anhedonia model of depression predicts antidepressant-like properties of the COMT inhibitor tolcaponeMoreau, J.-L. / Jenck, F. / Martin, J. R. / Mutel, V. et al. | 1995
- 169
-
Therapeutic potential of drugs acting on excitatory amino acid receptorsScatton, B. / Avenet, P. / Benavides, J. / Besnard, F. et al. | 1995
- 169
-
Molecular pharmacology of NMDA receptorsWilliams, K. et al. | 1995
- 170
-
Glutamate antagonists in animal models of cerebral ischaemiaMcCulloch, J. et al. | 1995
- 171
-
The pharmacology of CERETAT[TM] (CNSI 102) and early clinical resultsGamzu, E. et al. | 1995
- 171
-
Clinical treatment of ischaemic stroke: present and futureFieschi, C. / Cavalletti, C. / Montinaro, E. et al. | 1995
- 172
-
Treatment response to serotonin reuptake inhibitors in minor depressionsRosenbaum, J. F. et al. | 1995
- 172
-
Depression and the risk of mortalityGlassman, A. H. et al. | 1995
- 173
-
The optimal therapeutical area for SSRIs: panic disorderWade, A. G. et al. | 1995
- 173
-
SSRIs in the treatment of melancholic patientsRoose, S. P. / Glassman, A. H. / Attia, E. et al. | 1995
- 174
-
Obsessive compulsive disorder (OCD) and social phobiaBallenger, J. C. et al. | 1995
- 174
-
Differences between the SSRIBroesen, K. et al. | 1995
- 175
-
WHO international study of somatoform disorders - a review of methods and resultsJanca, A. et al. | 1995
- 175
-
The present nosography of somatoform disorders: results of the Italian epidemiological study of somatoform disordersTacchini, G. / Musazzi, A. / Recchia, M. / Altamura, A. C. et al. | 1995
- 175
-
Somatoform disorders and personality in the general population and in psychiatric outpatientsCloninger, C. R. et al. | 1995
- 176
-
Psychopharmacological treatments of somatoform disordersAltamura, A. C. et al. | 1995
- 176
-
The co-occurrence of panic and somatization disorder: analysis from a genetic-epidemiological vantage pointBattaglia, M. / Politi, E. / Bertella, S. / Bellodi, L. et al. | 1995
- 177
-
Impulse control and serotonergic drugs: commonalities and differences in animal modelsDe Vry, J. / Schreiber, R. / De Beun, R. et al. | 1995
- 177
-
Focus on biological basis of somatoform disordersDel Zompo, M. / Ruiu, S. / Severino, G. / Cherchi, A. et al. | 1995
- 177
-
New perspectives on physiopathology and therapy of somatoform diseasesFratta, W. / Diana, M. / Azzena, G. B. / Forgione, A. et al. | 1995
- 178
-
Therapeutic attempts in impulse control disordersLopez-Ibor, J. J. / Saiz Ruiz, J. et al. | 1995
- 178
-
Clinical, nonhuman primate and rodent studies on impulse controlLinnoila, M. / Virkkunen, M. / Higley, J. D. / Hall, F. S. et al. | 1995
- 179
-
Platelet markers in aggressionUebelhack, R. et al. | 1995
- 180
-
Regulation of gene expression in adult brainVanderhaeghen, J. J. / Schiffmann, S. N. / Mailleux, P. / Zhang, F. et al. | 1995
- 180
-
Psychiatric effects of the anabolic steroids: aggression and impulse dyscontrolKatz, D. L. / Pope, H. G. et al. | 1995
- 180
-
Multiple ATP receptors in the nervous system: new and widely-distributed drug targetsBarnard, E. A. et al. | 1995
- 181
-
Functional and pharmacological distinctions between subtypes of dopamine D-2 receptorsSpano, P. F. / Memo, M. / Missale, C. / Pizzi, M. et al. | 1995
- 181
-
Regulatory mechanisms of neurotrophic factor gene expression in the central nervous systemRiva, M. A. / Molteni, R. / Lovati, E. / Fumagalli, F. et al. | 1995
- 182
-
Differential induction of early gene expression in the CNS by antipsychoticsRogue, P. et al. | 1995
- 183
-
Provocation of panic as a tool for investigating the disorderBourin, M. et al. | 1995
- 183
-
Panic disorder and the serotonin systemWestenberg, H. G. M. / Den Boer, J. A. et al. | 1995
- 184
-
The relationship between panic and agoraphobiaKlein, D. F. et al. | 1995
- 184
-
SSRIs in panic disorderLecrubier, Y. et al. | 1995
- 185
-
Carbon dioxide hypersensitivity and panic spectrum disordersPerna, G. / Bellodi, L. et al. | 1995
- 185
-
Has the response of positive symptoms to antipsychotics changed?Kane, J. M. et al. | 1995
- 186
-
Are primary negative symptoms treatable?Barnes, T. R. E. / Phillips, M. A. et al. | 1995
- 187
-
Movement disorders - do "atypical" antipsychotics make a difference?Gerlach, J. et al. | 1995
- 187
-
Quality of life as an outcome variable in the treatment of schizophrenic patientsMeise, U. / Kemmler, G. / Holzner, B. et al. | 1995
- 188
-
Advantages of atypical antipsychotics in the maintenance treatment of schizophreniaKissling, W. et al. | 1995
- 188
-
Pharmacodynamic and pharmacokinetic profile of an "ideal" neuroleptic: is there any?Altamura, A. C. et al. | 1995
- 189
-
Broadening treatment perspectives of schizophrenia: a clinical update on seroquelFleischhacker, W. W. et al. | 1995
- 189
-
Early improvement predicts responseBech, P. et al. | 1995
- 189
-
When do antidepressant work?Derivan, A. T. et al. | 1995
- 190
-
Protein phosphorylation system as a biochemical marker to study onset of antidepressant actionPerez, J. / Mori, S. / Caivano, M. / Garbini, S. et al. | 1995
- 190
-
Can two week studies be used to establish efficacy?Montgomery, S. A. et al. | 1995
- 191
-
Therapeutic strategies for rapid onset and improved efficacy: present and futureDe Montigny, C. et al. | 1995
- 191
-
Enhanced antidepressant responses with antagonists of somatodendritic 5-HT~1~A receptors. Basic and clinical studiesArtigas, F. / Romero, L. / Bel, N. / Perez, V. et al. | 1995
- 192
-
Is there a role for neurosteroids in alcoholism?Romeo, E. / Pompili, E. / Di Michele, F. / Furnari, C. et al. | 1995
- 192
-
Animal models in alcohol researchColombo, G. / Agabio, R. / Balaklievskaia, N. / Lobina, C. et al. | 1995
- 193
-
Carbohydrate deficient transferrin (CDT) in comparison to other biological markers in alcoholismAckenheil, M. / Sanktjohannser, A. / Jenner, A. / Karlsson, M. et al. | 1995
- 194
-
Pharmacotherapeutic approaches in relapse preventionChick, J. D. et al. | 1995
- 194
-
Basic and clinical research leading to the use of naltrexone in the treatment of alcoholismO'Brien, C. P. / Volpicelli, J. R. et al. | 1995
- 195
-
Experience with naltrexone and psychotherapy in treating alcoholism in EuropeSoyka, M. et al. | 1995
- 196
-
Somatodendritic dopamine stimulates glutamate and GABA release via D~1 receptorsKalivas, P. W. / Lu, X.-Y. et al. | 1995
- 196
-
Involvement of the nigral D~1 receptor in neuroleptic-induced oral dyskinesias in rats: clinical implicationsTamminga, C. A. et al. | 1995
- 196
-
Dopamine D1 receptor activation decreases GABA release through adenosine A1 receptor after chronic cocaine treatmentWilliams, J. T. / Bonci, A. et al. | 1995
- 196
-
Functional role of somatodendritic dopamine release in basal ganglia circuitryAbercrombie, E. D. / Timmerman, W. / DeBoer, P. et al. | 1995
- 197
-
Subthreshold syndromes of depressionAngst, J. / Preisig, M. / Merikangas, K. R. et al. | 1995
- 197
-
Do antidepressants work in mild depression?Montgomery, S. A. et al. | 1995
- 198
-
Cross-over studies of chronic resistant depressionKeller, M. et al. | 1995
- 198
-
Acute and long-term pharmacotherapeutic strategies in pure dysthymia: efficacy of sertraline and imipramineKocsis, J. et al. | 1995
- 199
-
Pharmacotherapy of depression subtypesKasper, S. et al. | 1995
- 200
-
Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugsGallhofer, B. et al. | 1995
- 200
-
Managing the first episode of schizophrenia: the role of new therapiesMcCreadie, R. G. et al. | 1995
- 201
-
Treatment resistant schizophrenia: new insights into neurobiology and treatmentWeinberger, D. R. / Lipska, B. K. et al. | 1995
- 202
-
Treatment-resistant schizophrenia: clinical experience with new antipsychoticsDufour, H. / Bondolfi, G. / Baumann, P. / Seywert, F. et al. | 1995
- 202
-
Proper psychosocial rehabilitation for the stabilised schizophrenic patients: the role of new therapiesPeuskens, J. et al. | 1995
- 203
-
Underlying neurotransmitter changes in Alzheimer's diseaseFrancis, P. T. / Alder, J. T. / Chen, C. P. L.-H. / Chessell, I. P. et al. | 1995
- 203
-
The impact of managed care systems on relapse prevention and quality of life for patients with schizophreniaGlazer, W. M. et al. | 1995
- 204
-
Alzheimer's disease: neurochemistry of Alzheimer's disease and its clinical implicationsAmaducci, L. et al. | 1995
- 204
-
Treatment strategies in Alzheimer's diseaseLevy, R. et al. | 1995
- 205
-
Disease altering therapeutic strategies based on the molecular dissection of the amyloid lesions in Alzheimer's diseaseBeyreuther, K. / Masters, C. L. et al. | 1995
- 205
-
Xanomeline: the first study of the safety and efficacy of an M1 agonist in mild and moderate Alzheimer's diseaseBodick, N. C. / Offen, W. et al. | 1995
- 206
-
Pharmacological treatment of anxiety disorders: an overviewLepine, J. P. / Pelissolo, A. et al. | 1995
- 206
-
Defective protein kinase C and -amyloid precursor protein secretion in fibroblasts from sporadic Alzheimer's disease patientsGovoni, S. / Bergamaschi, S. / Trabucchi, M. / Battaini, F. et al. | 1995
- 207
-
MAOIs in social phobiaKatschnig, H. / Berger, P. et al. | 1995
- 207
-
Benzodiazepines in panic disorders: focus on clonazepamRosenbaum, J. F. et al. | 1995
- 208
-
Are there more effective drug treatments for obsessive compulsive disorder?Fineberg, N. A. / Roberts, A. / Montgomery, S. A. et al. | 1995
- 209
-
The role of serotonin in dysthymia and other affective spectrum diseasesKasper, S. et al. | 1995
- 209
-
5HT2C receptor agonists and antagonists in animal models of anxietyMartin, J. R. / Boes, M. / Jenck, F. / Koehler, C. et al. | 1995
- 210
-
Premenstrual mood disorders: clinical experience with serotonergic-based therapiesSteiner, M. et al. | 1995
- 210
-
OCD: the promise and limitation of serotonin selective agentsRavizza, L. et al. | 1995
- 210
-
Role of serotonin in psychosisFarde, L. / Nyberg, S. / Halldin, C. et al. | 1995
- 211
-
New alternatives for the pharmacotherapy of anxiety disordersDen Boer, J. A. / Van Megen, H. J. G. M. / Westenberg, H. G. M. et al. | 1995
- 212
-
The role of serotonin in emerging therapeutic opportunities: the beginning not the endTollefson, G. D. et al. | 1995
- 213
-
Novel neuroleptics acting on presynaptic dopaminergic receptorsScatton, B. / Perrault, G. / Gonon, F. / Depoortere, R. et al. | 1995
- 214
-
Dopaminergic influence on motivational processes: improving positive and/or negative symptomLecrubier, Y. / Boyer, P. et al. | 1995
- 214
-
Pharmacology of anhedoniaWillner, P. et al. | 1995
- 216
-
Acute and long-term treatment of schizophrenia: different strategies for positive and negative symptoms?Rein, W. et al. | 1995
- 216
-
Assessment of negative symptoms in the long-term treatment of psychosisKane, J. M. et al. | 1995
- 217
-
Endogenous cannabinoid ligands - chemical and biological studiesMechoulam, R. / Ben Shabat, S. / Hanus, L. / Fride, E. et al. | 1995
- 217
-
GABAergic drugs and addictive behaviorTempesta, E. / Janiri, L. / Mannelli, P. et al. | 1995
- 218
-
Is dopamine involved in opiate addiction?Van Ree, J. M. / Gerrits, M. A. F. M. et al. | 1995
- 218
-
Opioid receptor blockadeKosten, T. R. et al. | 1995
- 219
-
Opiate agonists and antagonists in the treatment of heroin addiction: differential outcomes according to methadone and naltrexone treatment practiceMannaioni, P. F. / Botti, P. / Caramelli, L. / Gambassi, F. et al. | 1995
- 219
-
The impact of depression on survival following myocardial infarctionLesperance, F. / Smith, N. F. / Talajic, M. et al. | 1995
- 220
-
Vital exhaustion, cardiac events, and the relationship to depressionKop, W. J. et al. | 1995
- 221
-
Anger, hostility and progression of arteriosclerotic diseaseSalonen, J. T. / Julkunen, J. / Kaplan, G. A. / Kauhanen, J. et al. | 1995
- 221
-
Mechanisms linking death and depressionGlassman, A. H. / Bigger, J. T. / Roose, S. P. et al. | 1995
- 222
-
Plasticity of astrocytes in agingVernadakis, A. / Kentroti, S. / Kazazoglou, T. / Fleischer Lambropoulos, E. et al. | 1995
- 222
-
Can antidepressants be used safely in patients with serious heart disease?Roose, S. P. / Glassman, A. H. / Woodring, S. et al. | 1995
- 223
-
Growth factors as products and regulators of astrocytes: CNTF, FGF, TGF-1-3, and GDNFUnsicker, K. / Meyer, V. / Flanders, K. C. / Wirth, S. B. et al. | 1995
- 223
-
Oxysterol (7-hydroxycholesteryl-3-oleate) promotes serotonergic reinnervation in the lesioned rat spinal cord by reducing glial reactionPrivat, A. / Gimenez y Ribotta, M. / Mersel, M. et al. | 1995
- 224
-
Enhanced extracellular glutamate and delayed neurotoxicity in cortical neuroglial cocultures exposed to the glutamate uptake inhibitor PDCVolterra, A. / Bezzi, P. / Lodi Rizzini, B. / Trotti, D. et al. | 1995
- 224
-
Neuron-glia interactions in glutamate and GABA homeostasis: implications for epilepsy and neurodegenerative diseasesSchousboe, A. et al. | 1995
- 224
-
Prevalence, lifecourse and disability in social phobiaJudd, L. L. et al. | 1995
- 225
-
WPA educational programme on social phobiaCosta e Silva, J. A. et al. | 1995
- 225
-
Basic and clinical aspects of social phobiaDen Boer, J. A. / Van Vliet, I. M. / Westenberg, H. G. M. et al. | 1995
- 226
-
Reversible inhibitors of monamine oxidase A (RIMA) in the treatment of social phobiaSiegel, J. L. et al. | 1995
- 227
-
Interaction of drugs and psychotherapy in social phobiaKatschnig, H. / Sachs, G. et al. | 1995
- 227
-
Subclinical and atypical forms of bipolarityCassano, G. B. et al. | 1995
- 227
-
Distinction of recurrent brief depression from other fluctuating brief depressions. Consequences for therapy evaluationBenkert, O. / Fickinger, M. P. / Philipp, M. / Heun, R. et al. | 1995
- 228
-
New treatments for bipolar disorderTohen, M. et al. | 1995
- 228
-
Is rapid cycling a valid subtype of bipolar disorder?Maj, M. / Magliano, L. / Pirozzi, R. / Marasco, C. et al. | 1995
- 229
-
Physiological function of the ventral striatumLe Moal, M. / Piazza, P. V. / Maccari, S. / Casolini, P. et al. | 1995
- 229
-
Evidence of the efficacy of maintenance-electroconvulsive therapy (M-ECT) in rapid cyclig bipolar disordersVanelle, J. M. / De Carvalho, W. / Olie, J. P. / Loo, H. et al. | 1995
- 229
-
Functional organization of the ventral striatum: focus on limbic-striatal loopsEveritt, B. J. et al. | 1995
- 230
-
Abnormal mesolimbic dopamine function following neonatal hippocampal damage: implications for schizophreniaLipska, B. K. / Lillrank, S. M. / Wood, G. K. / Weinberger, D. R. et al. | 1995
- 230
-
Dopaminergic hypofunction in the nucleus accumbens as a substrate for depressionWillner, P. et al. | 1995
- 231
-
Prefronto-cortical versus ventral striatal selectivity in the action of motivationally active drugs and stimuliDi Chiara, G. et al. | 1995
- 232
-
Free radical scavengers in neuroprotectionRiederer, P. / Gsell, W. / Froelich, L. / Goetz, M. et al. | 1995
- 232
-
Physiopathological role of glutamate receptors in mesencephalic neurons in vitroAmbrosini, A. / Bresciani, L. / Orlandi, V. / Fracchia, S. et al. | 1995
- 233
-
Evoked potentials monitoring in Parkinson's disease therapyStanzione, P. / Pierantozzi, M. / Semprini, R. / Traversa, R. et al. | 1995
- 234
-
Electrophysiological monitoring of dopaminergic therapy using short-latency median nerve somatosensory evoked potentials (SEPS) in Parkinson's diseaseMauguiere, F. et al. | 1995
- 234
-
The effect of treatment on motor cortical activity in Parkinson's diseaseRothwell, J. C. et al. | 1995
- 235
-
Psychoactive drugs and early social interactions in rodentsLaviola, G. / Terranova, M. L. et al. | 1995
- 235
-
Age-dependent behaviors and developmental psychopharmacology in the context of behavioral teratologySpear, L. P. et al. | 1995
- 236
-
The role of behavior in the assessment of developmental exposure to environmental pollutantsElsner, J. et al. | 1995
- 236
-
Neurobehavioral changes produced by developmental exposure to environmental pollutantsDe Salvia, M. A. / Carratu, M. R. / Cagiano, R. / Cortese, I. et al. | 1995
- 237
-
Ontogeny of firing patterns of dopamine neurons in rat midbrain slices. Role of NMDA receptor activationMereu, G. / Lilliu, V. / Vicini, S. / Casula, A. et al. | 1995
- 238
-
Animal models of developmental neurotoxicity and their relevance to human exposures: the example of leadWinneke, G. / Lilienthal, H. / Bonatz, A. et al. | 1995
- 238
-
Anatomical abnormalities in the temporal lobe in schizophreniaShenton, M. E. / McCarley, R. W. / Kikinis, R. / Hokama, H. H. et al. | 1995
- 239
-
Magnetic resonance imaging of the frontal lobe in schizophreniaHulshoff Pol, H. E. / Baare, W. F. C. / Gispen-de Wied, C. C. / Mali, W. P. T. M. et al. | 1995
- 239
-
Receptor binding studies in schizophreniaSedvall, G. et al. | 1995
- 240
-
Basal ganglia shrinkage in schizophrenia: magnetic resonance and neuropsychological studyRossi, A. / Stratta, P. / Mancini, F. / Mattei, P. et al. | 1995
- 240
-
Neuroanatomical abnormalities and symptomatology of schizophreniaVita, A. / Dieci, M. / Giobbio, G. M. / Caputo, A. et al. | 1995
- 241
-
Functional neuroimaging to evaluate atypical antipsychotic compounds: an FDG PET study of SDZ MAR 327Potkin, S. G. / Wu, J. / Fallon, F. / Anand, R. et al. | 1995
- 242
-
Mechanisms of chronic mild stress-induced anhedoniaPapp, M. et al. | 1995
- 242
-
Stress peptides and HPA axis reactivity in depressionNemeroff, C. B. / Stout, S. C. / Owens, M. J. et al. | 1995
- 242
-
Life events and the aetiology of depressionBrown, G. W. et al. | 1995
- 243
-
Implication of central and peripheral glutamate receptors in experimental stress ulcersBaraldi, M. / Truzzi, C. / Veneri, C. / Chiessi, C. et al. | 1995
- 244
-
Tumorigenesis and immune function in a transgenic mouse model of the endocrine changes seen in depression characterized by defective glucocorticoid feedback inhibition and HPA axis hyperactivityBlom, J. M. C. / Barden, N. / Racagni, G. et al. | 1995
- 244
-
Influences of stress and glucocorticoids on psychostimulant abusePiazza, P. V. / Deroche, V. / Rouge-Pont, F. / Haney, M. et al. | 1995
- 245
-
Psychopathology and prevalence of depression in Parkinson's diseaseRing, H. A. et al. | 1995
- 245
-
ECT in Parkinson's disease, with and without depressionTrimble, M. R. et al. | 1995
- 245
-
Interactions between dopaminergic, serotoninergic and nitric oxide-containing systems in the CNS. Their possible involvement in Parkinson's disease and depressionSteinbusch, H. W. M. et al. | 1995
- 246
-
Treatment of depression in Parkinson's disease: a meta-analysisVerhey, F. R. J. / Havermans, A. G. M. / Klaassen, T. / Van Praag, H. M. et al. | 1995
- 246
-
Parkinson's disease and depression: one disease?Martignoni, E. / Verri, A. P. / Nappi, G. et al. | 1995
- 247
-
Clinical aspects of anxiety states in the elderlyCasacchia, M. / Roncone, R. et al. | 1995
- 247
-
The biological basis and pharmacological treatment of anxiety: do the elderly differ?Leonard, B. E. et al. | 1995
- 248
-
The treatment of anxiety disorders in the elderlySheehan, D. V. / Ray, B. A. / Sheehan, K. H. et al. | 1995
- 248
-
The clinical decision in long-term treatment of anxiety disorders with benzodiazepinesPancheri, P. / Biondi, M. et al. | 1995
- 249
-
Chronicity and continuity in depressive stateCassano, G. B. / Cecconi, D. et al. | 1995
- 249
-
Pharmacological and clinical experience in nefazodone treatment of depressionPreakorn, S. H. et al. | 1995
- 250
-
The effects of nefazodone on sleep profiles in depressionArmitage, R. et al. | 1995
- 250
-
Modern approach in the treatment of anxiety associated with depressionKeller, M. B. et al. | 1995
- 250
-
Sexual dysfunction and other tolerability in the management of depressionBaldwin, D. et al. | 1995
- 251
-
Preclinical/clinical aspects of interactions between serotonin and norepinephrineBlier, P. et al. | 1995
- 251
-
Sleep and neuroendocrine profiles in depression and maniaLinkowski, P. / Mendlewicz, J. et al. | 1995
- 251
-
Pharmacotherapeutic profile of venlafaxinePreskorn, S. H. et al. | 1995
- 252
-
Rapid onset of action: clinical relevance to antidepressant actionMontgomery, S. A. et al. | 1995
- 253
-
Efficacy and safety of venlafaxine in major depressionLecrubier, Y. et al. | 1995
- 254
-
Xanomeline in mild and moderate Alzheimer's disease; the effects of a novel M1 agonist on behaviorBodick, N. C. / Offen, W. et al. | 1995
- 254
-
The discovery and pharmacology of xanomeline, a muscarinic M1 receptor agonist for Alzheimer's diseaseShannon, H. E. / Bymaster, F. P. / Calligaro, D. O. / DeLapp, N. W. et al. | 1995
- 254
-
An overview of CNS drug discovery at Eli Lilly and CompanyPaul, S. M. et al. | 1995
- 255
-
Olanzapine: an exciting atypical antipsychotic - the preclinical profileMoore, N. A. / Bymaster, F. P. / Calligaro, D. O. / Fuller, R. W. et al. | 1995
- 256
-
A randomized, naturalistic cost-effectiveness study in a managed health care settingHeiligenstein, J. H. / Simon, G. et al. | 1995
- 256
-
Olanzapine: an exciting atypical antipsychotic - the clinical experienceTollefson, G. D. / Beasley, C. M. / Tran, P. V. / Sanger, T. et al. | 1995
- 257
-
Biological enrichment in the study of drug: placebo differences of patients with affective disordersJames, S. / Heiligenstein, J. / Faries, D. / Tollefson, G. et al. | 1995
- 257
-
Adaptive randomization in clinical trials: a placebo compromiseWood, A. / Faries, D. / Heiligenstein, J. et al. | 1995
- 258
-
A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorderBlashko, C. A. et al. | 1995
- 259
-
The role of continuation treatment in chronic depressionKeller, M. / Zucker, M. E. et al. | 1995
- 259
-
Premenstrual dysphoric disorder: is it simply PMS?Endicott, J. et al. | 1995
- 260
-
Advances in the pharmacotherapy of obsessive-compulsive disorderBisserbe, J. C. et al. | 1995
- 260
-
The role of SSRIs in anxiety disordersNutt, D. et al. | 1995
- 261
-
Epidemiology and public health significance of depressive disordersJudd, L. L. et al. | 1995
- 262
-
The new antidepressant Org 3770 (mirtazapine) modulates noradrenergic and serotonergic transmission by blocking ~2-adrenergic autoreceptorsDe Boer, T. / Nefkens, F. / Van Helvoirt, A. et al. | 1995
- 262
-
Clinical efficacy of mirtazapineKasper, S. et al. | 1995
- 262
-
Neurobiology of antidepressant treatmentsDe Montigny, C. et al. | 1995
- 263
-
Safety of mirtazapineMontgomery, S. A. et al. | 1995
- 265
-
Assessment of changes in regional cerebral blood flow in patients with seasonal affective disorder (SAD) using single photon emission tomographyRieder, N. / Neumeister, A. / Podreka, I. / Kasper, S. et al. | 1995
- 265
-
Lithium-potassium cotransport across the erythrocyte membrane in affective disordersHiyama, T. / Yoshimuta, N. / Nakayama, K. / Ushijima, S. et al. | 1995
- 265
-
Guanine nucleotide binding proteins (G proteins) in drug-free depressed patientsKarege, F. / Bovier, P. / Schwald, M. / Stepanian, R. et al. | 1995
- 266
-
Clinical predictors of response to antidepressants in geriatric depressionsKoncevoy, V. A. / Andrusenko, M. P. / Sheshenin, V. S. et al. | 1995
- 266
-
The prevalence of psychotropic drug use in the population presenting to general practitioner in the urban area of PaduaBorgherini, G. / Semenzin, M. / Gardellin, F. / Giorgetti, R. et al. | 1995
- 266
-
Enhanced sensitivity to CCK-4 in women with severe premenstrual symptoms (PDD)Le Melledo, J. M. / Bradwejn, J. / Koszycki, D. / Bellavance, F. et al. | 1995
- 266
-
The effects of CCK-4 on plasma arginine-vasopressin and oxytocin levels in women with and without premenstrual dysphoric disorderLe Melledo, J. M. / Bradwejn, J. / Koszycki, D. / Bellavance, F. et al. | 1995
- 267
-
Clinical efficacy of left and right unilateral electroconvulsive seizures in affective disorders and schizophreniaNikolaenko, N. N. / Egorov, A. Y. et al. | 1995
- 267
-
Thyrotropin response to thyrotropin-releasing hormone in depressionBunevicius, R. et al. | 1995
- 267
-
ACTH, prolactin, cortisol after dexamethasone in mental illnesses with postmenopausal onsetsMolnar, G. et al. | 1995
- 268
-
Evolution of platelet and plasma serotonin levels following electroconvulsive therapy in patients with major depressive episodeQuintin, P. / Spreux-Varoquaux, O. / Kollenbach, K. / Gregoire, A. et al. | 1995
- 268
-
Eye fixations and recognition memory in depressionFleury, E. / Buquet, C. / Thomas, P. / Goudemand, M. et al. | 1995
- 268
-
Space perception changes as a result of cognitive dysfunction in affective disorders and schizophreniaEgoroy, A. Y. / Nikolaenko, N. N. / Freiman, E. A. / Dobrovolskaya, N. V. et al. | 1995
- 269
-
Light therapy is able to prevent the relapse after partial sleep deprivationNeumeister, A. / Rieder, N. / Goessler, R. / Lucht, M. et al. | 1995
- 269
-
Short-term availability of brain serotonin in crucial for antidepressant effect of light therapyNeumeister, A. / Rieder, N. / Hesselmann, B. / Kasper, S. et al. | 1995
- 269
-
Prevalence of psychiatric comorbidity in patients with diabetes mellitus type I with and without poor metabolic controlEiber, R. / Balssa, N. / Grimaldi, A. / Lecrubier, Y. et al. | 1995
- 270
-
The depression unknown to the general practitionerZdanowicz, N. / Reynaert, C. / Janne, P. / Boriani, M. et al. | 1995
- 270
-
Cortical and subcortical brain changes in bipolar affective disorders: a magnetic resonance imaging studyPuzynski, S. / Beresewicz, M. / Koszewska, I. / Poniatowska, R. et al. | 1995
- 270
-
Plasma prolactin level in major depression and antidepressant therapyLandowski, J. / Sowinski, P. / Wichowicz, H. et al. | 1995
- 270
-
Cerebral blood flow pattern of treatment responsiveness in major depressionThomas, P. / Vaiva, G. / Maron, M. / Baux, P. et al. | 1995
- 271
-
Three months activity report of 104 Italian psychiatric centresPancheri, P. / Marconi, P. L. et al. | 1995
- 271
-
Study of anticipation in bipolar affective disorderHeiden, A. M. / Miller-Reiter, E. / Willinger, U. / Meszaros, K. et al. | 1995
- 271
-
Mood disorder with maniac features in a patient treated with GM-C.S.F.Zdanowicz, N. / Chatelain, C. / Wulleman, P. / Reynaert, C. et al. | 1995
- 272
-
Suicidal behavior in depression: role of serotonin and noradrenalinePitchot, W. / Ansseau, M. / Hansenne, M. / Moreno, A. G. et al. | 1995
- 272
-
Endothelium released factors in depressionBianchi, A. / Pitari, G. M. / Candido, P. / Colucci D'Amato, C. et al. | 1995
- 272
-
Depression and suicide on gotland, before and after the depression-training program for general practitionersRihmer, Z. / Pihlgren, H. / Rutz, W. et al. | 1995
- 273
-
Treatment resistant depression - a biochemical hypothesisGupta, R. K. / Burrows, G. D. / Norman, T. et al. | 1995
- 273
-
Red blood cell L-tryptophan uptake in depression: a putative indicator of the antidepressant drug choice?Jeanningros, R. / Serres, F. / Azorin, J. M. / Dassa, D. et al. | 1995
- 273
-
Depression and direct central serotonin (5-HT)Becker, U. / Laakmann, G. / Baghai, T. / Pfeiffer, B. et al. | 1995
- 274
-
Are Wistar-Kyoto rats a genetic animal model of depression?: similarities with humans in the temporal response to imipramineLahmame, A. et al. | 1995
- 274
-
Influence of some psychotropic drugs on the anti-immobility effects of serotonin reuptake inhibitors in the forced swimming test in miceThiebot, M.-H. / Da-Rocha, M. A. / Puech, A. J. et al. | 1995
- 274
-
Additive effects of glyburide and antidepressants in the forced swimming test: further evidence for involvement of the potassium channelsGuo, W. Y. / Todd, K. / Bourin, M. / Hascoet, M. et al. | 1995
- 275
-
Effects of co-administration of anxiolytic-drugs on reversal by serotonin uptake inhibitors of deficit behavior in learned helplessness paradigmMartin, P. / Lacroix, P. / Billardon, M. / Guillou, N. et al. | 1995
- 275
-
The additive effects of quinine on antidepressants in the forced swimming test in miceGuo, W. Y. / Todd, K. / Bourin, M. et al. | 1995
- 275
-
Measure of neuroreceptors and behaviour in a putative chronobiological model of affective disordersSchelstraete, I. / Jeanjean, A. P. / Weyer, M. H. / Maloteaux, J. M. et al. | 1995
- 276
-
Effect of sigma ligands on NMDA receptor function in the bulbectomy model of depression: a behavioural study in the ratDebonnel, G. / Dryver, E. / Lavoie, N. et al. | 1995
- 276
-
Antidepressant effects of milnacipran in the learned helplessness test in ratsLacroix, P. / Rocher, N. / Gandon, J. M. / Panconi, E. et al. | 1995
- 276
-
The antidepressant effects of 5-HT1A agonist buspirone in the learned-helplessness paradigm: a post-synaptic mediationMartin, P. et al. | 1995
- 277
-
An investigation of the acute effects of sertraline in a rat social interaction testLightowler, S. / Kennett, G. A. / Tulloch, I. F. / Blackburn, T. P. et al. | 1995
- 277
-
A rapid antidepressant response may be induced by selectively activating postsynaptic serotonin~1~a receptorsBergeron, R. / De Montigny, C. / Blier, P. et al. | 1995
- 278
-
Pindolol potentiates the effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleusDavidson, C. / Stamford, J. A. et al. | 1995
- 278
-
Acute and chronic effects of imipramine on serotonergic function. Microdialysis studies in conscious ratsArtigas, F. / Bel, N. et al. | 1995
- 279
-
Effects of selective antidepressants on the sensitivity of the central alpha-2-adrenergic receptorsBabinski, T. / Totc, S. / Marinkovic, D. / Stanisavljevic, D. et al. | 1995
- 279
-
Changes in the subcellular distribution of cAMP receptors after chronic treatment with fluvoxamine and paroxetineMori, S. / Caivano, M. / Garbini, S. / Dorigo, A. et al. | 1995
- 279
-
Protein kinase c activity and distribution in brain after chronic treatment with antidepressantsHrdina, P. D. / Mann, C. D. / Vu, T. B. et al. | 1995
- 280
-
Chronic antidepressant administration inhibits microtubule assembly in rat cerebral cortexMiyamoto, S. / Asakura, M. / Sasuga, Y. / Imafuku, J. et al. | 1995
- 280
-
Effects of lithium on rat brain energy metabolismImafuku, J. / Pettegrew, J. W. et al. | 1995
- 281
-
Neuropeptides in central nervous system. Effects of lithium and electroconvulsive treatmentWahlund, B. / Stenfors, C. / Jimenez, P. / Haij, K. et al. | 1995
- 281
-
Motor effects of some selective serotonin reuptake inhibitors following direct injection into the red nucleus of the rat: evidence for involvement of sigma receptorsLeonard, B. E. / Faherty, C. / Earley, B. et al. | 1995
- 281
-
Effect of lithium on inositol triphosphate formation in rat brain as determined by in vivo microdialysisGur, E. / Newman, M. E. / Lerer, B. et al. | 1995
- 281
-
Pharmacological differences between selective serotonin reuptake inhibitors: interaction with 5-HT~2 and sigma binding sites in human brain in vitroTulloch, J. F. / Lowther, S. / Crompton, M. R. / De Paermentier, F. et al. | 1995
- 282
-
Contribution of lysosomal trapping to the tissue uptake of desipramine; its significance for pharmacokinetics and the pharmacokinetic interactionDaniel, W. / Bickel, M. H. / Honegger, U. E. et al. | 1995
- 282
-
The influence of different amitriptyline doses on its concentrations and pharmacokineticsMiljkovic, B. / Pokrajac, M. / Timotijevic, I. et al. | 1995
- 283
-
The Citalopram Challenge Test (CCT) as a probe for serotonergic function in depressionKapitany, T. / Schindler, S. D. / Barnas, C. / Neumeister, A. et al. | 1995
- 283
-
Interactions between mianserin and opioid receptor subtype selectivityPick, C. G. / Backer, M. M. / Schreiber, S. et al. | 1995
- 283
-
Involvement of serotoninergic system in the analgesic effect of tricyclic antidepressantsGhelardini, C. / Galeotti, N. / Bartolini, A. et al. | 1995
- 284
-
Fluoxetine, a selective 5-hydroxytryptamine uptake inhibitor, increases the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonistMaj, J. / Rogoz, Z. / Skuza, G. et al. | 1995
- 284
-
An autoradiographic comparison of ^3H-paroxetine and ^3H-imipramine in human whole brain sectionsMiller, J. / Bowery, N. / Tulloch, I. et al. | 1995
- 284
-
Effects of paroxetine and bupropion on event-related potentials and spectral frequencyCamp-Bruno, J. A. / Lifshitz, K. / Lee, K. / Linn, G. S. et al. | 1995
- 285
-
Action of reboxetine on selective drug metabolizing enzymes in rat liverFiorentini, F. / Oesch, F. / Arand, M. / Castelli, M. G. et al. | 1995
- 285
-
Cerebral metabolic effects of fluvoxamine: an it in vivo [^1^4C]2-deoxy-D-glucose study in ratsFreo, U. / Pietrini, P. / Pizzolato, G. / Merico, A. et al. | 1995
- 285
-
The dopamine system is involved in antidepressant sleep deprivation - a possible mechanismon of antidepressant action?Ebert, D. / Albert, R. / May, A. / Kaschka, W. P. et al. | 1995
- 286
-
Tryptophan and Serotonin in Panic Disorder and Depression: Effect of Clomipramine TreatmentFekkes, D. / Timmerman, L. / Pepplinkhuizen, L. et al. | 1995
- 286
-
Pharmacotherapy of depression in combination therapy with anxiolytics in non-comorbid depressive patientsMolnar, G. et al. | 1995
- 286
-
Efficacy of fluoxetine in comparison to maprotiline and amitriptyline in major depression with anxious featuresBugarski-Kirola, D. / Totic, S. / Damjanovic, A. / Zivkovic, D. et al. | 1995
- 287
-
Fluoxetine treatment of bulimia nervosaVega, M. / Chinchilla, A. / Cebollada, A. / Padin, J. J. et al. | 1995
- 287
-
Psychopharmacological treatment of anorexia nervosaCebollada, A. / Chinchilla, A. / Vega, M. / Padin, J. J. et al. | 1995
- 287
-
Double-blind comparison of three fixed doses of sertraline and placebo in patients with panic disorderDuBoff, E. / England, D. / Ferguson, J. M. / Londborg, P. D. et al. | 1995
- 288
-
Fluvoxamine induced change of 5 HT receptor sensitivity in impulsive borderline personality disorderRinne, T. / Gans, E. / Vernimmen, R. / Den Boer, J. A. et al. | 1995
- 288
-
The treatment of eating disorders with tianeptinAtchkova, M. et al. | 1995
- 288
-
Practical aspects of long-term treatmentMalt, U. F. et al. | 1995
- 289
-
The factor of antidepressant treatment response in dysthymiaVeltischev, D. Y. / Gurevich, J. M. / Seravina, O. F. et al. | 1995
- 289
-
The treatment of dysthymia with sertraline: a double-blind placebo-controlled trial in dysthymic outpatients without major depressionGuelfi, J. D. / Wiseman, R. L. et al. | 1995
- 289
-
Stability as a factor of tricyclic antidepressants response in dysthymiaVeltischev, D. Y. / Gurevich, J. M. / Seravina, O. F. et al. | 1995
- 290
-
Assessment of the evolution of anxiety during a treatment of major depressive disorders in ambulatory patients in general practice with fluoxetine (Prozac) 20 mgMesters, P. / Martens, S. / Taymans, J. et al. | 1995
- 290
-
Therapeutical approach to dysthymiaFernandez, G. / Ocio, S. et al. | 1995
- 290
-
The treatment of dysthymia patients: fluvoxamine versus amitriptylineAmore, M. / Ricci, M. / Zazzeri, N. et al. | 1995
- 291
-
Up-regulation of 5-HT~2~C receptors by citalopram and fluoxetine in rat brainSyvaelahti, E. K. G. / Laakso, A. / Paelvimaeki, E.-P. / Kuoppamaeki, M. et al. | 1995
- 291
-
Onset of action of fluoxetine 20 mg (Prozac) among ambulatory patients suffering from depressive disordersMesters, P. / Sangeleer, M. / Bussios, G. / Bourgeois, M. et al. | 1995
- 291
-
The effects of fluoxetine in patients receiving nutritional counselling for bulimia nervosaRussell, J. / Beumont, P. / Touyz, S. / Buckley, C. et al. | 1995
- 292
-
Clinical differences in response to mianserin and fluoxetine in depressive patientsLavergne, F. / Berlin, I. / Payan, C. / Besancon, G. et al. | 1995
- 292
-
Combined treatment with serotonin reuptake selective inhibitors in depression (II). Aspects concerning tolerance and toxicity in clinical practiceSoto Loza, A. A. / Franch Valverde, J. I. / Rodriguez Montes, M. J. / Dorado Martinez, M. L. et al. | 1995
- 292
-
Combined treatment with serotonin reuptake selective inhibitors in depression (I). Evaluation of therapeutic efficacyFranch Valverde, J. I. / Soto Loza, A. A. / Rodriguez Montes, M. J. / Dorado Martinez, M. L. et al. | 1995
- 293
-
Dosulepine - an adjuvant treatment of oncological painBastecky, J. / Tondlava, H. / Jakoubkova, J. et al. | 1995
- 293
-
Idiopathic blepharospasm treated successfully with fluoxetine: do SSRI's have some dopaminergic effect?Schreiber, S. / Pick, C. G. et al. | 1995
- 293
-
Antidepressants and neuroleptic malignant syndromeAssion, H. J. / Heinemann, F. / Laux, G. et al. | 1995
- 294
-
Acute and subchronic effects of mirtazapine (15/30 mg nocte) and mianserin (30/60 mg nocte) on psychomotor and actual driving performance and sleep in healthy, young volunteersRamaekers, J. G. / Muntjewerff, N. D. / O'Hanlon, J. F. et al. | 1995
- 294
-
Sleep quality and day-time alertness in responders and non-responders to fluoxetineDossenbach, M. / Meszaros, K. / Meyer, J. W. et al. | 1995
- 294
-
Possible association of suicidal behavior with selective serotonin reuptake inhibitors. The effect of citalopram on five depressed patientsTrikkas, G. / Markianos, M. / Trikka, D. et al. | 1995
- 295
-
Efficacy of antidepressant medications for treatment of mild and moderate depressionFonzo, V. / Scotta, M. / Rocca, P. / Zanalda, E. et al. | 1995
- 295
-
Compliance with different classes of antidepressant drugsKoutouvidis, N. / Zacharakis, C. et al. | 1995
- 295
-
Changes in acute phase proteins in depressed patients, during treatment with fluoxetine and venlafaxineSluzewska, A. / Hoerning-Rohan, M. / Sobieska, M. / Rybakowski, J. K. et al. | 1995
- 296
-
Pharmacotherapy in depression during switch from depression to mania in patients with bipolar affective disorder (BD)Koszewska, I. et al. | 1995
- 296
-
Multiple and single dose pharmacokinetics of milnacipran in major depressive patientsRetz, W. / Becker, T. / Schmidtke, A. / Riederer, P. et al. | 1995
- 296
-
Serotonin-related symptoms and adrenergic status in depressed patients treated with clomipramineLejoyeux, M. / Rouillon, F. / Ades, J. et al. | 1995
- 297
-
Moclobemide in the treatment of depressive syndrome in schizophreniaJasovic-Gasic, M. / Nikolic-Balkoski, G. / Totic, S. / Acimovic, B. et al. | 1995
- 297
-
The possibilities of automid (moclobemide) administration in the treatment of affective disordersTimotijevic, I. / Kovacevic, S. / Tomovic, A. / Kostic, D. et al. | 1995
- 298
-
Treatment of severe recurrent major depression: comparative efficacy and tolerability of moclobemide and imipramineHochstrasser, B. / Ferrero, F. / Gachoud, J.-P. / Gasser, U. E. et al. | 1995
- 298
-
Efficacy of moclobemide-therapy in depressed patientsRadics, J. et al. | 1995
- 298
-
Dimensional assessment of onset of action of antidepressants - a comparative study of moclobemide versus clomipramine in depressed patients with blunted affect and psychomotor retardationJouvent, R. / Payan, C. / Mikkelsen, H. / Fermanian, J. et al. | 1995
- 299
-
Delusional depression: SSRIs vs tricyclics responsivenessConte, G. / Calzeroni, A. / Ferrari, R. / Guarneri, L. et al. | 1995
- 299
-
SSRIs: a homogeneous class of antidepressants with non homogeneous responsiveness in major depressionConte, G. / Calzeroni, A. / Guarneri, L. / Pergami, A. et al. | 1995
- 299
-
Comparison of the effects of nefazodone and fluoxetine on sleep architecture and sleep efficiency in depressed patientsArmitage, R. / Yonkers, K. / Rush, A. J. / Cole, D. et al. | 1995
- 300
-
Pharmacokinetics of reboxetine in healthy volunteers of different agesJannuzzo, M. G. / Ryde, M. / Karlmark, B. / Roenn, O. et al. | 1995
- 300
-
Dopamine receptor binding in major depression: changes before and after treatment with selective serotonin reuptake inhibitorsKlimke, A. / Larisch, R. / Janz, A. / Vosberg, H. et al. | 1995
- 300
-
Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteersFiorentini, F. / Poggesi, I. / Jannuzzo, M. G. / Seiberling, M. et al. | 1995
- 300
-
Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteersJannuzzo, M. G. / Bosc, M. / Renoux, A. / Dostert, P. et al. | 1995
- 301
-
Endocrine response to lithium challenge in unmedicated rapid-cycling patientsWhybrow, P. / Redei, E. / Gyulai, L. et al. | 1995
- 301
-
Lithium treatment and suicide prevention in affective disordersAhrens, B. et al. | 1995
- 301
-
Open comparative study of lithium carbonate, carbamazepine and sodium valproate prophylactic use in affective and schizoaffective disordersMosolov, S. N. / Kostukova, E. G. / Kouzavkova, M. V. et al. | 1995
- 302
-
Experience with lithium/fluvoxamine combination: 36 casesHopwood, S. E. / Ashford, J. J. / Prescott, P. et al. | 1995
- 302
-
Comparison of carbamazepine and beta-endorphin levels in manic states treatmentProcic, V. A. et al. | 1995
- 302
-
A pilot study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymiaFava, M. / Nierenberg, A. A. / Quitkin, F. M. / Zisook, S. et al. | 1995
- 303
-
Sleep in depressed outpatients during treatment with fluvoxamine - a home-based studyWilson, S. J. / Bell, C. / Coupland, N. J. / Nutt, D. J. et al. | 1995
- 303
-
Fluvoxamine reduces somatic symptoms and is well tolerated in elderly depressed patients: results from the oldest reported population treated with a selective serotonin reuptake inhibitorJaquenoud, E. / Hochstrasser, B. / Kat, M. et al. | 1995
- 304
-
Comparison of the safety and tolerance of fluvoxamine and sertraline in depressed outpatientsNemeroff, C. B. / Ninan, P. T. / Ballenger, J. C. / Feighner, J. et al. | 1995
- 304
-
Safety and tolerability of fluvoxamine in adolescent depressionAlfonso, M. / Ferrer, R. / Such, P. et al. | 1995
- 304
-
Comparison of fluvoxamine and fluoxetine in major depressionRapaport, M. / Coccaro, E. / Sheline, Y. / Holland, P. et al. | 1995
- 305
-
Antidepressant actions on peripheral visual detection mechanisms in humansWeinstein, A. / Wilson, S. / Bailey, J. / Nutt, D. et al. | 1995
- 305
-
A multicentre study of nefazodone and sertraline in depressed outpatientsBurns, T. / Kosky, N. / Balasubramaniam, K. / D'Souza, J. et al. | 1995
- 306
-
Perspectives of use of calcium channels blockers for treatment of affective disorders (experimental data)Kozlovsky, V. L. et al. | 1995
- 306
-
Down regulation of 5-HT~2~A receptors after chronic treatment with remeronBerendsen, H. H. G. / Broekkamp, C. L. E. / Van Delft, A. M. L. et al. | 1995
- 306
-
A multicentre comparison of nefazodone and paroxetine in depressed outpatientsBaldwin, D. / Hawley, C. / Abed, R. / Maragakis, B. et al. | 1995
- 307
-
Cardiac safety of venlafaxineDanjou, P. et al. | 1995
- 307
-
An overview of the dose-response efficacy of venlafaxine with respect to treatment in different subclassifications of depressive illnessGuichoux, J. Y. / Hackett, D. et al. | 1995
- 307
-
Effect of venlafaxine on rate and extent of improvement of depressive symptomsHackett, D. / Haudiquet, V. / Danjou, P. et al. | 1995
- 308
-
A randomized double-blind comparison of venlafaxine, imipramine and placebo in general practice patients with mild moderate depressionBlanchard, C. / Hackett, D. / Danjou, P. / Nicholas, T. et al. | 1995
- 308
-
A randomised, double-blind, comparison of the efficacy and safety of venlafaxine (75 to 150 mg/day) versus fluoxetine (20 mg/day) in depressed outpatientsSalinas, E. / Nicholas, T. / Hackett, D. et al. | 1995
- 308
-
Acute and continuation therapy with sertraline in major depression: a large-scale multicenter studyFloris, M. / De Nayer, A. R. / Janssen, F. / Van Houdenhove, B. et al. | 1995
- 309
-
The effects of trazodone on sleep: a clinical and EEG study in patients with major depressionArriaga, F. / Paiva, T. / Cavaglia, F. / Pinheira, G. et al. | 1995
- 309
-
A naturalistic prospective study of the efficacy and tolerability of fluoxetine in 244 unselected psychiatric outpatients. The importance of co-morbidity as a predictor of responseBlacker, C. V. R. et al. | 1995
- 309
-
A double-blind, multicentre study in primary care comparing paroxetine and clomipramine in patients with depression with associated anxietyHunter, B. et al. | 1995
- 310
-
Trazodone and sleep disturbances induced by brofaromineHaffmans, P. M. J. / Vos, M. S. et al. | 1995
- 310
-
Efficacy and safety of mirtazapine vs trazodone in hospitalised depressed patientsVan Moffaert, M. et al. | 1995
- 310
-
Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepineWiklander, B. / Danjou, P. / Rolan, P. / Tamin, S. K. et al. | 1995
- 311
-
The efficacy of tianeptine: an Indian study of one hundred and sixteen non-psychotic depressed patientsParikh, R. M. / Sonwalla, S. B. / Shah, L. P. / Doshi, B. S. et al. | 1995
- 311
-
Effect of clomipramine versus placebo on social adjustment in residual depressionRouillon, F. / Waintraub, L. / Markabi, S. / Lancrenon, S. et al. | 1995
- 311
-
Paroxetine for treating depression in adolescentsRodriguez Ramos, P. / Sans, M. J. M. / Cabases, J. S. S. / De Dios Vega, J. L. et al. | 1995
- 312
-
Fluoxetine in therapy of persons with PTSDSmalc, V. F. / Folnegovic, Z. / Kocijan, D. / Kozaric, D. et al. | 1995
- 312
-
The influence of doxepine treatment upon the changes of triglycerides and cholesterol level in anorexic patientsRajewski, A. / Rajewska, J. / Chlebowski, T. et al. | 1995
- 312
-
Neuroleptics in the therapy of delusional depressionCvjetkovic, M. / Knezevic, A. / Nedic, A. et al. | 1995
- 313
-
Fluvoxamin (Avoxin-KRKA) in the pharmacotherapy of mood disorders in elderlyMahnik, M. / Hotujac, L. / Vukelja, D. / Mandic, K. et al. | 1995
- 313
-
Treatment of depressions in elderly GP-patientsMikhailova, N. M. et al. | 1995
- 313
-
Clinical efficacy of paroxetine in elderly outpatientsZarattini, F. / Testa, L. et al. | 1995
- 314
-
Sertraline: an assessment of clinical benefit and cost in the UKJohnson, N. J. / Lane, R. et al. | 1995
- 314
-
Double-blind comparison of sertraline and nortriptyline in late-life depressionFinkel, S. I. / Richter, E. M. et al. | 1995
- 314
-
SSRIs in the treatment of depressed out patients aged 70 years and olderNewhouse, P. A. / Finkel, S. I. / Richter, E. M. et al. | 1995
- 315
-
An open study of sertraline in fibromyalgia syndromeSyuertsen, J. O. / Smedsrud, T. / Lane, R. M. et al. | 1995
- 315
-
Analysis of the Hamilton depression rating scale factors - fluoxetine vs. maprotilineStankovic, Z. / Zivkovic-Milovanovic, D. / Bugarski-Kirola, D. / Damjanovic, A. et al. | 1995
- 315
-
The non-responding major depressive patient - the treatment-refractory major depressive patientDrolsum, B. A. et al. | 1995
- 315
-
Combined therapy in treating poststroke depressionMarko, M. et al. | 1995
- 316
-
Plasma concentration of MCPP after single oral dose administration of trazodone and MCPP in humansLawlor, B. A. / Radcliffe, J. / Sunderland, T. / Murphy, D. L. et al. | 1995
- 316
-
The neurochemical and behavioural effects of the isomers of mirtazapine in normal ratsNorman, T. R. / McGrath, C. J. / Burrow, G. D. et al. | 1995
- 316
-
Effects of befloxatone on psychomotor performance and cognitive functions in elderly subjectsPatat, A. / Gandon, J. M. / Le Coz, F. / Durrieu, G. et al. | 1995
- 317
-
Outcome predictors in first episode schizophreniaAmore, M. / Magnani, K. / D'Ambrosio, S. / Mesa Mesa, J. et al. | 1995
- 317
-
Effect D.N. Uznadze in paranoid schizophrenics: clinical and treatment perspectivesPkhidenko, S. V. et al. | 1995
- 317
-
Soluble interleukin-6 receptors in schizophrenia: preliminary resultsMueller, N. / Empl, M. / Putz, A. / Schwarz, M. et al. | 1995
- 318
-
Are regional cerebral blood flow studies using single photon emission computed tomography (SPECT) reproducible in schizophrenia? Presentation of the protocolWalter, M. / Leboul, D. et al. | 1995
- 318
-
Investigating dopamine receptor binding with PET and SPECT ligands in schizophrenia: clinical and methodological considerationsKlimke, A. / Boy, C. / Mueller-Gaertner, H. W. / Gaebel, W. et al. | 1995
- 318
-
Predictors of treatment compliance in long-term mentally illMiddelboe, T. et al. | 1995
- 319
-
Differential effects of S-ketamine and R-ketamine on psychopathology and brain energy metabolism measured by FDG-PET in humansVollenweider, P. X. / Leenders, K. L. / Oeye, I. / Scharfetter, C. et al. | 1995
- 319
-
Eye fixations and recognition memory in schizophreniaFleury, E. / Buquet, C. / Thomas, P. / Goudemand, M. et al. | 1995
- 320
-
Impaired performance on tests sensitive to fronto-subcortical dysfunction is related to both the positive and the negative dimensions of schizophreniaMignone, M. L. / D'Amato, A. C. / Saviano, P. / Mucci, A. et al. | 1995
- 320
-
Cerebral ventricles in chronic schizophrenia and ageingMedvedev, A. V. / Valova, O. A. / Savvateeva, N. J. U. / Zharkova, N. B. et al. | 1995
- 320
-
Increased allergic reactivity of atopic type in major psychosesDabkowska, M. / Rybakowski, J. K. et al. | 1995
- 321
-
Functional etiology of schizophrenia as a new approach for specific treatmentTrimarchi, M. / Papeschi, L. L. / Russo, P. / Persegani Trimarchi, C. et al. | 1995
- 321
-
Clinical dimensions and neuroleptic dosage in newly admitted schizophrenic patientsTroisi, A. / Spalletta, G. / De Angelis, F. / Inzerilli, G. et al. | 1995
- 321
-
Leucocyte arylsulphatase A activity in schizophrenia and depressionMihaljevi Peles, A. / Jakovljevic, M. / Kracun, I. / Cacic, A. et al. | 1995
- 322
-
Fenfluramine challenge test in schizophreniaMohr, P. / Sramova, L. / Libiger, J. et al. | 1995
- 322
-
Anhedonia, displeasure capacity and blunted affect in schizophreniaBoyer, P. / Loas, G. / Legrand, A. et al. | 1995
- 322
-
New peculiarities of schizophrenic patients' reaction on psychopharmacotherapyMalyarov, S. A. et al. | 1995
- 322
-
Vitamin B12 and folic acid deficiency in psychiatric in-patientsSwiecicki, L. M. et al. | 1995
- 323
-
Indices of serotonergic activity in suicidal patients with schizophrenic, affective and adjustment disorderHawellek, B. / Rao, M. L. / Papassotiropulos, A. / Deister, A. et al. | 1995
- 323
-
Studies on platelet serotonin system in hospitalized schizophrenicsFolnegovic-Smalc, V. / Jernej, B. / Kozaric-Kovacic, D. / Makaric, G. et al. | 1995
- 323
-
Cannabis abuse and neurological abnormalities in schizophrenia: preliminary findingsBjoerck, R. V. / Nordin, C. et al. | 1995
- 324
-
Is it true that schizophrenia is only mental disorder?Ilankovic, N. / Ilankovic, V. et al. | 1995
- 324
-
Modelling attentional deficits in schizophrenia: hippocampal subfield lesions and performance of a 5-choice reaction time task in the ratBratt, A. M. / Stacey, K. / Chase, R. M. / Mittleman, G. et al. | 1995
- 324
-
Neuroleptic effectiveness prognosing in paranoid schizophrenia (clinical and neurophysiological aspects)Yurieva, L. N. / Nosov, S. G. et al. | 1995
- 325
-
Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosesManor, I. / Hermesh, H. / Ratzoni, G. / Munitz, H. et al. | 1995
- 325
-
MR imaging of selected brain structures and clinical improvement in schizophreniaJarema, M. / Choma, M. / Poniatowska, E. et al. | 1995
- 325
-
Lack of myoglobinuria in acute psychosis with marked elevation in serum creatinine kinaseHermesh, H. / Manor, I. / Weizman, R. / Munitz, H. et al. | 1995
- 326
-
Antipsychotic drugs differentially affect neurosteroid-induced modulation of the [^3H]NE release evoked by NMDA in the rat hippocampusMonnet, F. P. / Baulieu, E. E. et al. | 1995
- 326
-
Treatment of schizophrenia with immunosuppressantsShinitzky, M. et al. | 1995
- 326
-
Autoimmune response against autologous platelets in schizophrenia - a basis for novel diagnostic and therapeutic approachesDeckmann, M. / Shinitzky, M. / Leykin, I. / Cheng, D. et al. | 1995
- 326
-
The Lidingoe investigationFlyckt, L. / Taube, A. / Edman, G. / Petterson, I. et al. | 1995
- 327
-
Induction of c-fos gene expression by the sigma receptor ligand and potential neuroleptic drug EMD 57445 in rat brainDahmen, N. / Fischer, V. / Hoedl, P. / Rujescu, D. et al. | 1995
- 327
-
Central effects of EMD 57445, a new sigma receptor ligand with a potential antipsychotic activityMaj, J. / Skuza, G. / Rogoz, Z. et al. | 1995
- 327
-
D2-receptor occupancy related to neuroleptical doses, side effects and prolactin levels: a study with IBZM-SPECTSchlegel, S. / Schloesser, R. / Hiemke, C. / Nickel, O. et al. | 1995
- 328
-
Haloperidol and pimozide withdrawal: a comparison of behavioral and biochemical effectsMichaluk, J. / Romanska, I. / Vetulani, J. / Antkiewicz-Michaluk, L. et al. | 1995
- 328
-
The effect of neuroleptics on the AP-1 DNA binding activity and the induction of fos and junOzaki, T. / Katsumoto, E. / Yokotani, N. / Yamagami, S. et al. | 1995
- 328
-
The effect of chlorpromazine on the induction of c-fos by electroconvulsive shock in the regions of rat brainKim, Y. S. / Ahn, Y. M. / Kang, U. G. / Park, J.-B. et al. | 1995
- 329
-
Selective activation by risperidone on serotonin but not dopamine metabolism in the rat prefrontal cortexNomikos, G. G. / Hertel, P. / Marcus, M. / Iurlo, M. et al. | 1995
- 329
-
Effect of BIMG 80, a novel potential atypical antipsychotic, on dopamine levels measured by microdialysisVolonte, M. / Cerutti, M. / Giraldo, E. / Gil, M. et al. | 1995
- 329
-
Pharmacological profile of BIMG 80, a novel potential atypical antipsychoticBrambilla, A. / Cesana, R. / Gil, M. / Borsini, F. et al. | 1995
- 330
-
Antagonism of apomorphine-induced spontaneous eyeblinks in the rhesus monkey: possible differences among the antipsychotics haloperidol, risperidone, and remoxiprideKleven, M. S. / Koek, W. et al. | 1995
- 330
-
In vitro and ex vivo patterns of occupation of 5-HT~2~A and ~1-adrenergic as compared to dopamine D~2 receptors by novel antipsychoticsAudinot, V. / Canton, H. / Newman-Tancredi, A. / Jacques, V. et al. | 1995
- 330
-
Comparative profiles of interaction of atypical antipsychotics at cloned human dopamine hD~2, hD~3 and hD~4 receptors: S 16924 shows a marked preference for hD~4 sitesAudinot, V. / Newman-Tancredi, A. / Jacques, V. / Chaput, C. et al. | 1995
- 331
-
Pharmacology of the potential antipsychotic EMD 57445 in animals and humansBartoszyk, G. D. / Bender, H. M. / Heusener, A. / Schnorr, C. et al. | 1995
- 331
-
Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profileNeedham, P. L. / Skill, M. J. / Heal, D. J. et al. | 1995
- 332
-
Binding of zotepine and other antipsychotics to cloned human dopamine receptorsNeedham, P. L. / Atkinson, J. / Heal, D. J. et al. | 1995
- 332
-
d-Amphetamine-induced abnormal behavior in the rat antagonized by SCH 23390 or racloprideSalmi, P. / Svensson, T. H. / Ahlenius, S. et al. | 1995
- 332
-
The pre-clinical profile of the new antipsychotic ziprasidoneO'Connor, R. / Harrigan, E. et al. | 1995
- 332
-
Seroquel[TM]: new pre-clinical research data confirm atypical antipsychotic actionsGoldstein, J. M. et al. | 1995
- 333
-
Double-blind study of zotepine vs haloperidol in schizophreniaPetit, M. / Raniwalla, J. / Leutenegger, E. / Tweed, J. A. et al. | 1995
- 333
-
Sexual dysfunctions induced by typical and atypical antipsychoticsHummer, M. / Kurz, M. / Oberbauer, H. / Kurzthaler, I. et al. | 1995
- 333
-
Haloperidol and reduced haloperidol discriminate sigma receptor subtypes in the neuronal response to N-methyl-D-aspartate in the rat hippocampusMonnet, F. P. / Bowen, W. D. / Baulieu, E. E. et al. | 1995
- 334
-
Antipsychotic treatment of different subtypes of schizophreniaBrazo, P. / Dollfus, S. / Zarifian, E. / Petit, M. et al. | 1995
- 334
-
Disturbed thermoregulation in haloperidol-treated outpatients with chronic schizophreniaHermesh, H. / Manaim, H. / Epstein, Y. / Birger, M. et al. | 1995
- 334
-
The use of antipsychotic medication in France and Great Britain: similarity or divergence?Dollfus, S. / Van Os, J. / Petit, M. et al. | 1995
- 335
-
Levosulpiride vs pimozide in negative symptoms of schizophreniaDe Ronchi, D. / Ruggeri, M. / Balelli, G. / Volterra, V. et al. | 1995
- 335
-
The use of anti-Parkinsonian drugs in hospitalized, psychotic patients on depot neurolepticsDrolsum, B. A. / Johnsen, T. et al. | 1995
- 335
-
Sulpiride and risperidone vs. "classical neuroleptics" in schizophrenia: a follow-up studyKogeorgos, J. / Kanellos, P. / Michalakeas, A. / Ioannidis, J. et al. | 1995
- 336
-
Pharmaco EEG effects of DU29894 - a new dopamine antagonist and serotonin agonistDietrich, B. / De Koning, P. et al. | 1995
- 336
-
Low doses of amisulpride in negative schizophrenia: A 99m-Tc HMPAO SPECT studyVaiva, G. / Thomas, P. / Dutoit, D. / Fleury, E. et al. | 1995
- 336
-
Clinical effects of I-sulpiride vs haloperidol in acutely relapsed chronic schizophrenics: therapeutic efficacy on "disorganization"?Guazzelli, M. / Barracchia, E. / Bertolino, A. et al. | 1995
- 337
-
IBZM-SPECT and D2 dopamine receptor occupancy: different profiles with atypical neurolepticsKuefferle, B. / Bruecke, T. / Tauscher, J. / Schratzberger-Topitz, A. et al. | 1995
- 337
-
Patient requests and attitude towards neurolepticsHoencamp, E. / Knegtering, H. / Kooy, J. J. S. / Van tier Moolen, A. E. G. M. et al. | 1995
- 337
-
NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. A phase II clinical trialKarle, J. / Gerlach, J. / Clemmesen, L. / Hansen, L. et al. | 1995
- 337
-
Risperidone compared to novel and reference antipsychotic drugs for the in vivo occupancy of rat brain neurotransmitter receptorsSchotte, A. / Janssen, P. F. M. / Bonaventure, P. / Leysen, J. E. et al. | 1995
- 338
-
Zuclopenthixol acetate in the treatment of psychotic anxietyRomain, J. L. / Dermain, P. / Gresle, P. / Moisan, P. et al. | 1995
- 338
-
Sleep evaluation in out-patients with oral neurolepticsHaffmans, P. M. J. / Oolders, H. / Hoencamp, E. / Arends, J. et al. | 1995
- 338
-
The anticholinergic-neuroleptic association: a possible cause of confusional state in elderly peoplePrincipe, L. / De Notaris, E. / Pillo, G. et al. | 1995
- 339
-
Psychosocial adjustment during neuroleptic continuation treatment: a study with the life skills profile in 200 DSM-IV chronic schizophrenic outpatientsZizolfi, S. / Boreggio, M. / Carfi', S. / Centorame, F. et al. | 1995
- 339
-
Clozapine treatment of young subjects affected with schizophreniaBruno, V. et al. | 1995
- 339
-
Clozapine induces improvement in very severe treatment-resistant schizophrenic patients: an open study on "depression" in schizophreniaGiordano, L. / Schiazza, G. / Tiberti, T. / Nistico, R. et al. | 1995
- 340
-
Therapy-resistant schizophrenia: a psychopharmacotherapeutic approach with an atypical antipsychotic drug (clozapine)Giannelli, A. / Volonte, M. V. et al. | 1995
- 340
-
Adhesion to the treatment and relapses decrease with clozapineLupinski, C. C. et al. | 1995
- 341
-
Clozapine quantitative EEG profile: a multilead investigationBucci, P. / Romano, G. / Tresca, E. / Mucci, A. et al. | 1995
- 341
-
Clinical efficacy of clozapine during the initial weeks of treatment. Effect on negative symptomsLlorca, P. M. / Reine, G. / Lancon, C. / Auquier, P. et al. | 1995
- 341
-
Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patientsLee, M.-S. / Kim, S.-H. et al. | 1995
- 341
-
A two years follow-up of treatment-refractory schizophrenics treated with clozapineVampini, C. / Steinmayr, M. / Bilone, F. / Meruzzi, G. et al. | 1995
- 342
-
The role played by clozapine in the psycho-social rehabilitation program for chronic schizophrenic patients who present mostly negative symptomsNicotra, M. C. / Bilone, F. / Robotti, C. A. et al. | 1995
- 342
-
Improvement of positive and negative symptoms during clozapine treatment in neuroleptic-resistant schizophrenicsJalenques, J. / Albuisson, E. et al. | 1995
- 342
-
Clinical efficacy of clozapine in treatment-refractory schizophrenic patientsLee, M.-S. / Jung, I.-K. / Kwak, D.-I. et al. | 1995
- 343
-
Prevention of relapse in schizophrenia with clozapine: an open mirror-image study of 53 outpatients treated up to 8 yearsKlimke, A. / Klieser, E. et al. | 1995
- 343
-
Clozapine: the Indian experience with eighty-two patients of treatment resistant chronic schizophreniaSonawalla, S. / Parikh, R. M. et al. | 1995
- 343
-
Recurrence of transient near granulopenia but not true granulopenia during the initiation/early phase, of clozapine therapyHermesh, H. / Valevski, A. / Dorfman-Etrog, P. / Weisman, A. et al. | 1995
- 343
-
Relapse prevention with clozapine in schizophrenic outpatients: plasma level, metabolism and complianceKlimke, A. / Henning, U. et al. | 1995
- 344
-
Prospective four year follow-up study on clozapine treated patients: SPECT-HMPAO and clinical evaluationMedved, V. / Hotujac, L. / Petrovic, R. / Dodig, D. et al. | 1995
- 344
-
Response to clonidine-haloperidol association in schizophrenic relapse predicts outcome of haloperidol-noradrenergic or serotoninergic antidepressant associationConte, G. / Calzeroni, A. / Ferrari, R. / Guarneri, L. et al. | 1995
- 344
-
Serum clozapine levels and clinical response - results of therapeutic drug monitoringGrabe, H.-J. / Rahn, R. / Greb, T. / Rao, M. L. et al. | 1995
- 344
-
Long term side effects in schizophrenia outpatients under neuroleptic treatmentChinchilla, A. / Vega, M. / Cebollada, A. / Padin, J. J. et al. | 1995
- 345
-
Neuroleptic malignant syndrome following abrupt neuroleptic withdrawalBelelli, G. / Pezzoli, A. / Muraccini, R. et al. | 1995
- 345
-
Mild neuroleptic malignant syndrome: problems of differential diagnosisBelelli, G. / Pezzoli, A. et al. | 1995
- 346
-
Seroquel[TM] treatment of hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia. A multicentre, placebo-controlled, double-blind studyLink, C. G. G. / Arvanitis, L. et al. | 1995
- 346
-
Autoradiographic comparison of D~2- and D~3-dopamine receptor localization in the post mortem human brain using [^1^2^5I]epidepride and [^3H]PD 128907Hall, H. / Halldin, C. / Suzuki, M. / Dijkstra, D. et al. | 1995
- 346
-
Seroquel[TM] and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. A multicentre, double-blind controlled studyLink, C. G. G. / Smith, A. / Ryan, J. et al. | 1995
- 346
-
Seroquel[TM] treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimensLink, C. G. G. / Arvanitis, L. et al. | 1995
- 347
-
Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroquel[TM] tidGefvert, O. / Lindstrom, L. H. / Langstrom, B. / Bergstrom, M. et al. | 1995
- 347
-
Effect of olanzapine on deficit syndrome symptoms in chronic schizophreniaRevicki, D. / Genduso, L. et al. | 1995
- 347
-
Olanzapine versus haloperidol therapy for chronic schizophrenia: impact on deficit syndromeRevicki, D. / Genduso, L. et al. | 1995
- 347
-
Acute and long-term results of the North American double-blind olanzepine trialTran, P. V. / Beasley, C. M. / Tollefson, G. D. / Beuzen, J. N. et al. | 1995
- 348
-
Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patientsTargum, S. / Zborowski, J. / Henry, M. / Schmitz, P. et al. | 1995
- 348
-
Olanzapine in the treatment of dopaminomimetic psychosisWolters, E. C. et al. | 1995
- 348
-
Two open-label, long-term safety studies of sertindoleDaniel, D. / Staser, J. / Schmitz, P. / Sebree, T. et al. | 1995
- 349
-
Clinical efficacy of risperidone in idiopathic segmental dystoniaZuddas, A. / Carta, M. / Muglia, P. / DeMontis, N. et al. | 1995
- 349
-
A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophreniaBondolfi, G. / Baumann, P. / Patris, M. / May, J. P. et al. | 1995
- 349
-
Ritanserin in neuroleptic induced akathisia: a double blind comparison with placeboDe Col, C. / Miller, C. H. et al. | 1995
- 350
-
Risperidone in the treatment of schizophrenia: a double-blind comparison with haloperidolMurasaki, M. / Miura, S. et al. | 1995
- 350
-
Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter studyEmsley, R. A. / McCreadie, R. / Livingston, M. / De Smedt, G. et al. | 1995
- 350
-
Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophreniaJones, B. / De Smedt, G. / Lemmens, P. et al. | 1995
- 351
-
Efficacy of risperidone in treatment of paranoid symptoms in Alzheimer's disease (A.D.) and vascular dementia (V.D.)Wittgens, W. / Klieser, E. / Trenckmann, U. / Beine, K. et al. | 1995
- 351
-
Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open studyRossi, A. / Mancini, F. / Marola, V. / Stratta, P. et al. | 1995
- 351
-
Risperidone in schizophrenia; clinical and biochemical results in 28 patients suffering from an acute psychotic episodeVerhoeven, W. M. A. / Hofma, E. / Van den Berg, Y. W. M. M. / Kan, C. et al. | 1995
- 351
-
The efficacy and safety profile of a new antipsychotic, ziprasidone, in phase II studiesBradbury, J. E. / Heym, J. et al. | 1995
- 352
-
Cost and benefits of clozapine at the CHG de LagnyLochu, A. / Colen de Melo, P. / Roche-Rabreau, D. et al. | 1995
- 352
-
Zuclopenthixol in the treatment of positive/negative schizophrenic symptomsJarema, M. / Szafranski, T. / Bialek, J. et al. | 1995
- 352
-
Improvement in tardive dyskinesia, laterality of TD and cognition in schizophrenic patients changed from typical neuroleptics in risperidoneWilliams, R. / Dickson, R. / Caliguiri, M. / Mahoney, A. et al. | 1995
- 353
-
Study of penicillin antiulcer and behavioural effects in rats (some new possibilities for its pharmacology)Kalueff, A. V. et al. | 1995
- 353
-
Behavioral, monoaminergic, neuroendocrine and neuropeptidergic alterations in grown nonhuman primates exposed to unpredictable early rearing: relevance to human anxietyCoplan, J. D. / Andrews, M. W. / Rosenblum, L. A. / Owens, M. J. et al. | 1995
- 354
-
Influence of predictable and unpredictable chronic stress on phosphorylation of microtubule-associated proteins (MAPs) in rat brainAsakura, M. / Sasuga, Y. / Miyamoto, S. / Imafuku, J. et al. | 1995
- 354
-
Alterations in nucleus accumbens dopamine receptors and in amphetamine-induced sensitization in prenatally stressed ratsHenry, C. / Guegant, G. / Cador, M. / Le Moal, M. et al. | 1995
- 354
-
Modulation of serotonin metabolism with 5-HT~1 agonistic compounds in self injurious behaviorVerhoeven, W. M. A. / Tuinier, S. et al. | 1995
- 355
-
CSF 5-HIAA and aggression; is there a relationship indeed?Tuinier, S. / Verhoeven, W. M. A. et al. | 1995
- 355
-
Impulsive decision making in rats: the effects of drugs on a paced FCN8 scheduleEvenden, J. L. et al. | 1995
- 355
-
Endogenous opioids and stereotyped behaviorTuinier, S. / Verhoeven, W. M. A. et al. | 1995
- 356
-
Familial risk for panic disorder in panic patients: the effect of carbon dioxide sensitivityPerna, G. / Bertani, A. / Caldirola, D. / Bellodi, L. et al. | 1995
- 356
-
The 35% CO~2 challenge test in social phobics: preliminary resultsCaldirola, D. / Perna, G. / Arancio, C. / Cocchi, S. et al. | 1995
- 356
-
The effects of paroxetine and imipramine treatments on 35% CO~2 sensitivity in panic patientsBertani, A. / Perna, G. / Cocchi, S. / Gabriele, A. et al. | 1995
- 357
-
Efficiency of fluoxetine and dothiepine in treatment of panic disorder measured by 7% CO~2 challenge responseBocola, V. / Del Trecco, M. / Sollecito, A. / Paladini, C. et al. | 1995
- 357
-
Stress: what kind of therapy?Princet, P. et al. | 1995
- 358
-
Panic disorder - acceptance of the diagnostic entity and preferred treatmentBandelow, B. / Roethemeyer, M. / Hajak, G. / Ruether, E. et al. | 1995
- 358
-
Validation of the new panic and agoraphobia scale in a clinical studyBandelow, B. / Beinroth, D. / Hajak, G. / Ruether, E. et al. | 1995
- 358
-
Predictors of time to relapse in a longitudinal study of panic disorderPollack, M. H. / Otto, M. W. / Sabatino, S. / McCardle, E. et al. | 1995
- 358
-
What treatments do patients with panic disorder and agoraphobia get?Bandelow, B. / Sievert, K. / Hajak, G. / Broocks, A. et al. | 1995
- 359
-
Diagnostic problems of somatoform disorders: a study comparing ICD-10 and DSM-III-RSironi, J. / Tacchini, G. / Isaac, M. / Janca, A. et al. | 1995
- 359
-
From DSM-III-R to DSM-IV: a study of the threshold problem of somatoform disordersSironi, J. / Isaac, M. / Janca, A. / Tacchini, G. et al. | 1995
- 359
-
Heart rate and MHPG as predictors of nonresponse to drug therapy in panic disorderSlaap, B. R. / Van Vliet, I. M. / Westenberg, H. G. M. / Den Boer, J. A. et al. | 1995
- 360
-
A comparison of somatoform disorders in ICD-10 and DSM-IV: diagnostic consistency and internal validityJanca, A. / Tacchini, G. / Isaac, M. / Sironi, J. et al. | 1995
- 360
-
Social phobia: a risk factor for eating disorders?Flament, M. F. / Godart, N. et al. | 1995
- 360
-
Personality traits and platelet serotonergic measuresKozaric-Kovacic, D. / Jernej, B. / Folnegovic-Smalc, V. / Ljubin, T. et al. | 1995
- 361
-
Long-term evaluation of paroxetine, clomipramine and placebo in panic disorderDunbar, G. / Judge, R. et al. | 1995
- 361
-
Paroxetine, clomipramine and placebo in the treatment of panic disorderJudge, R. / Dunbar, G. et al. | 1995
- 361
-
A fixed dose study of paroxetine (10 mg, 20 mg, 40 mg) and placebo in the treatment of panic disorderDunbar, G. / Steiner, M. / Oakes, R. / Gergel, I. et al. | 1995
- 361
-
A double blind study comparing a combined plant extract with placebo in the treatment of anxietyBourin, M. / Bougerol, T. / Guitton, B. / Broutin, E. et al. | 1995
- 362
-
The influence of metabolites on ferment status of white blood cells and students' psychological peculiaritiesTernovsky, L. N. / Ternovskaya, V. A. / Ignateva, S. N. et al. | 1995
- 362
-
Correlation of ferment status, of lymphocytes, electrocardiography readings and corrective test in workers of cellulose-paper industryTernovsky, L. N. / Ternovskaya, V. A. / Nartsissov, R. P. et al. | 1995
- 363
-
Immune cell responses as indicators of different 5-HT receptor sensitivity in high and low impulsivesHennig, J. / Becker, H. / Netter, P. et al. | 1995
- 363
-
Maintenance of remission in panic disorder: issues for cognitive-behavior therapy, pharmacotherapy, and their combinationOtto, M. W. / Pollack, M. H. / Gould, R. A. / Sabatino, S. A. et al. | 1995
- 363
-
The professional deformation of the personality from the point of view of deontologyTernovsky, L. N. / Ternovskaya, V. A. et al. | 1995
- 364
-
Peripheral monoamines and CCK~4-induced panic attacks in healthy subjectsJerabek, I. / Boulenger, J. P. / Jolicoeur, F. B. / Bradwejn, J. et al. | 1995
- 364
-
An evaluator blind, randomised, comparison of the safety and efficacy of alprazolam SR and clomipramine in panic disorderHolland, R. L. / Musch, B. C. et al. | 1995
- 364
-
Short- and long-term discontinuation of alprazolam in patients with panic disorder with agoraphobiaCorrigan, H. / Jonas, M. / Reimherr, F. / Targum, S. et al. | 1995